Selected article for: "China Hubei province and fatality rate"
Author: Bassetti, Matteo; Vena, Antonio; Giacobbe, Daniele Roberto
Title: The novel Chinese coronavirus (2019‐nCoV) infections: Challenges for fighting the storm
  • Cord-id: e220ut9u
  • Document date: 2020_2_5
    • ID: e220ut9u
    Snippet: Since end of December 2019, a cluster of patients with pneumonia of unknown origin was reported from Wuhan, Hubei province, China. They shared a connection with the Huanan South China Seafood Market in Wuhan, and now it has been confirmed that the disease is caused by a novel coronavirus (provisionally named 2019-nCoV). As of today (30 January 2020), 7734 cases have been confirmed in China, and 90 cases have also been cumulatively reported from Taiwan, Thailand, Vietnam, Malaysia, Nepal, Sri Lan
    Document: Since end of December 2019, a cluster of patients with pneumonia of unknown origin was reported from Wuhan, Hubei province, China. They shared a connection with the Huanan South China Seafood Market in Wuhan, and now it has been confirmed that the disease is caused by a novel coronavirus (provisionally named 2019-nCoV). As of today (30 January 2020), 7734 cases have been confirmed in China, and 90 cases have also been cumulatively reported from Taiwan, Thailand, Vietnam, Malaysia, Nepal, Sri Lanka, Cambodia, Japan, Singapore, Republic of Korea, United Arab Emirate, United States, The Philippines, India, Australia, Canada, Finland, France, and Germany (Finland, France and Germany are the only European countries in which cases [n= 1, n = 5, and n = 4, respectively] have been reported up to date). According to the released news, the case rate fatality is 2.2% (170/7824).

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and lopinavir ritonavir available: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lopinavir ritonavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir remdesivir antiviral: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and low bind affinity: 1
    • acute respiratory syndrome and low case fatality rate: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lymphopenia leukopenia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir available: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir remdesivir antiviral: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute sars cov respiratory syndrome coronavirus and low bind affinity: 1
    • acute sars cov respiratory syndrome coronavirus and low case fatality rate: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and lymphopenia leukopenia: 1, 2, 3, 4
    • lopinavir ritonavir and low case fatality rate: 1
    • lopinavir ritonavir and lymphopenia leukopenia: 1, 2, 3, 4
    • lopinavir ritonavir remdesivir and lymphopenia leukopenia: 1